Combined GLP-1 and GLP-2 treatment appears safe but does not beat placebo for obesity
Can combining two gut hormone pathways unlock better obesity treatments? In the first human trial of dapiglutide, researchers found encouraging metabolic signals but no statistically significant edge over placebo, highlighting both the promise and the limits of next-generation dual agonists. Trial: Dapiglutide, a dual GLP-1 and GLP-2 receptor agonist, for obesity: a randomised, double-blind, placebo-controlled … Read more